本帖最后由 老马 于 2012-1-13 21:20 编辑
9 d# e$ Q: @2 n- O) K9 ]7 G7 d' O% [* g! k, J, N
爱必妥和阿瓦斯丁的比较
) u% b- K& O2 K2 _+ V% j
" M. H" R U( jhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
5 G1 w6 y- n/ j# t
: R$ w& S4 F" |. P# b
Z! w5 X/ v3 E& x$ Ihttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/9 S# p. z- S0 `* ]4 v! |! b2 M/ P m
==================================================
|* S8 j* o" f/ ~% q4 Z: dOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)% m- ?" n3 m( T9 V5 r% _' f
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 k" M% v' C% z1 e1 g/ B" mResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
l7 D. D( K) a3 s0 M$ d7 f& z
|